Cuprina Holdings Regains Nasdaq Compliance After 30-Day Sub-$1 Period, Hearing Canceled
CUPR•Cuprina Holdings regained compliance with Nasdaq’s $1.00 bid price requirement on June 11, 2026, after closing below the threshold for 30 consecutive business days. The company’s appeal led to the cancellation of its scheduled July 7 hearing, and its Class A shares remain listed on the Nasdaq Capital Market.
1. Regained Nasdaq Compliance
On June 11, 2026, Cuprina Holdings achieved full compliance with the Nasdaq Capital Market’s minimum bid price requirement by closing above $1.00 per share. This milestone removes the risk of delisting and secures uninterrupted trading of its Class A Ordinary Shares.
2. Delisting Appeal and Hearing Cancellation
Following a Staff Delisting Determination Letter issued on May 29, which cited a 30-day sub-$1 closing period, Cuprina appealed for a hearing before the Nasdaq Hearing Panel. Nasdaq Listing Qualifications staff subsequently confirmed compliance, leading to cancellation of the July 7 hearing.
3. Business Outlook
With listing compliance restored, Cuprina’s leadership plans to focus on commercialization of its chronic wound care, infertility, medical waste recycling and cosmeceutical products. CEO David Quek emphasized continued growth initiatives across multiple biomedical sectors moving forward.
